Astellas is a global pharmaceutical organisation formed from the merger of Yamanouchi and Fujisawa with 15,000 people worldwide, sales of over US $7.5 billion and global R&D spend of $1.4 billion (19%). Our medicines provide the promise of a healthier life globally, for therapeutic areas including Transplantation, Anti-Infectives, Dermatology and Urology.

Astellas Letter of Recommendation